Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2018

01-01-2018 | Editorial

PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer’s question

Authors: A. Gallamini, M. Meignan

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2018

Login to get access

Excerpt

In image-based clinical trials, when the study endpoint depends on treatment response assessment by imaging, blinded independent central review (BICR) is considered mandatory to overcome potential image reader bias leading to a systematic over- or under-interpretation of tumor shrinkage [1, 2]. …
Literature
1.
Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26:3791–6.CrossRef
2.
Amit O, Bushnell W, Dodd L, et al. Blinded Indipendent central review of progression-free survival endpoint. Oncologist. 2010;15:492–5.CrossRef
3.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.CrossRef
4.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphoma working group. J Clin Oncol. 2014;32:3048–58.CrossRef
5.
Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–607.CrossRef
6.
Straus DJ, Pitcher B, Kostakoglu L, et al. Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). Blood. 2015;126:578. [abstr.]
7.
André MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment of stage I and II Hodgkin Lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–94.CrossRef
8.
Gallamini A, Rossi A, Patti C, et al. Interim PET-adapted chemotherapy in advanced Hodgkin Lymphoma (HL). Results of the second interim analysis of the Italian GITIL/FIL HD 0607 trial. Hematol Oncol. 2015;33(Suppl. 1 June 2015):163. Abstract 118
9.
Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–29.CrossRef
10.
Press OW, Li H, Shoder H, et al. US Intergroup trial of response adapted for stage III to IV Hodgkin Lymphoma using early interim Fluorodeoxyglucose -Positron Emission Tomography imaging: Southwest Oncology Group S 0816. J Clin Oncol. 2016;34:2020–7.CrossRef
11.
Borchmann P, Havenkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced-stage Hodgkin’s lymphoma treated BEACOPP ESCALATED alone or in combination with Rituxinab (HD18): an open-label, international randomized phase 3study by the German Hodgkin Study Group. Lancet Oncol. 2017;18(4):454–63.CrossRef
12.
Casasnovas O, Brice P, Bouabdallah R, et al. Randomized phase III trial comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin Lymphoma: interim analysis of the AHL2011 Lysa Study. Blood. 2015;126:577. [abstr.]
13.
Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin Lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824–33.CrossRef
14.
Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin Lymphoma study. Blood. 2016;127(12):1531–8.CrossRef
15.
Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90.CrossRef
16.
Cohen J. A coefficient for agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46.CrossRef
17.
Hayes AS, Krippendorf K. Answering the call for a standard reliability measure for coding data. Commun Method Meas. 2007;1:77–89.
18.
Kobe C, Kuhnert G, Kahraman D, et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014;32:1776–81.
19.
Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27:2739–41.
20.
Chauvie S, Biggi A, Stancu A et al: WIDEN: a tool for medical image management in clinical trials. Clinical Trial 2014;0:1–7.
21.
Ceriani L, Barrington S, Biggi A, et al. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. Hematol Oncol. 2016. https://​doi.​org/​10.​1002/​hon.​2339.
Metadata
Title
PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer’s question
Authors
A. Gallamini
M. Meignan
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3841-y

Other articles of this Issue 1/2018

European Journal of Nuclear Medicine and Molecular Imaging 1/2018 Go to the issue

Original Article

Clinical impact of PSMA-based 18F–DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy

Original Article

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617

Society Communications

EANM Springer Prizes awarded at EANM’ 17 Vienna

Original Article

Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma

Editorial Commentary

Imaging the multiple facets of immuno-oncology

Original Article

Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy